Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment

Hiroyasu Kaneda, Takeshi Yoshida, Isamu Okamoto

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The discovery of activating mutations in the epidermal growth-factor receptor (EGFR) gene in 2004 opened a new era of personalized treatment for non-small-cell lung cancer (NSCLC). EGFR mutations are associated with a high sensitivity to EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib. Treatment with these agents in EGFR-mutant NSCLC patients results in dramatically high response rates and prolonged progression-free survival compared with conventional standard chemotherapy. Subsequently, echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK), a novel driver oncogene, has been found in 2007. Crizotinib, the first clinically available ALK tyrosine kinase inhibitor, appeared more effective compared with standard chemotherapy in NSCLC patients harboring EML4-ALK. The identification of EGFR mutations and ALK rearrangement in NSCLC has further accelerated the shift to personalized treatment based on the appropriate patient selection according to detailed molecular genetic characterization. This review summarizes these genetic biomarker-based approaches to NSCLC, which allow the instigation of individualized therapy to provide the desired clinical outcome.

Original languageEnglish
Pages (from-to)91-101
Number of pages11
JournalCancer Management and Research
Volume5
Issue number1
DOIs
Publication statusPublished - May 29 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Mutation
erbB-1 Genes
Therapeutics
Drug Therapy
Oncogenes
Patient Selection
Disease-Free Survival
Molecular Biology
Biomarkers
anaplastic lymphoma kinase
MAP4

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. / Kaneda, Hiroyasu; Yoshida, Takeshi; Okamoto, Isamu.

In: Cancer Management and Research, Vol. 5, No. 1, 29.05.2013, p. 91-101.

Research output: Contribution to journalReview article

@article{b39c2b4271a4479c986a4545293cd0d8,
title = "Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment",
abstract = "The discovery of activating mutations in the epidermal growth-factor receptor (EGFR) gene in 2004 opened a new era of personalized treatment for non-small-cell lung cancer (NSCLC). EGFR mutations are associated with a high sensitivity to EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib. Treatment with these agents in EGFR-mutant NSCLC patients results in dramatically high response rates and prolonged progression-free survival compared with conventional standard chemotherapy. Subsequently, echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK), a novel driver oncogene, has been found in 2007. Crizotinib, the first clinically available ALK tyrosine kinase inhibitor, appeared more effective compared with standard chemotherapy in NSCLC patients harboring EML4-ALK. The identification of EGFR mutations and ALK rearrangement in NSCLC has further accelerated the shift to personalized treatment based on the appropriate patient selection according to detailed molecular genetic characterization. This review summarizes these genetic biomarker-based approaches to NSCLC, which allow the instigation of individualized therapy to provide the desired clinical outcome.",
author = "Hiroyasu Kaneda and Takeshi Yoshida and Isamu Okamoto",
year = "2013",
month = "5",
day = "29",
doi = "10.2147/CMAR.S32973",
language = "English",
volume = "5",
pages = "91--101",
journal = "Cancer Management and Research",
issn = "1179-1322",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment

AU - Kaneda, Hiroyasu

AU - Yoshida, Takeshi

AU - Okamoto, Isamu

PY - 2013/5/29

Y1 - 2013/5/29

N2 - The discovery of activating mutations in the epidermal growth-factor receptor (EGFR) gene in 2004 opened a new era of personalized treatment for non-small-cell lung cancer (NSCLC). EGFR mutations are associated with a high sensitivity to EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib. Treatment with these agents in EGFR-mutant NSCLC patients results in dramatically high response rates and prolonged progression-free survival compared with conventional standard chemotherapy. Subsequently, echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK), a novel driver oncogene, has been found in 2007. Crizotinib, the first clinically available ALK tyrosine kinase inhibitor, appeared more effective compared with standard chemotherapy in NSCLC patients harboring EML4-ALK. The identification of EGFR mutations and ALK rearrangement in NSCLC has further accelerated the shift to personalized treatment based on the appropriate patient selection according to detailed molecular genetic characterization. This review summarizes these genetic biomarker-based approaches to NSCLC, which allow the instigation of individualized therapy to provide the desired clinical outcome.

AB - The discovery of activating mutations in the epidermal growth-factor receptor (EGFR) gene in 2004 opened a new era of personalized treatment for non-small-cell lung cancer (NSCLC). EGFR mutations are associated with a high sensitivity to EGFR tyrosine kinase inhibitors, such as gefitinib and erlotinib. Treatment with these agents in EGFR-mutant NSCLC patients results in dramatically high response rates and prolonged progression-free survival compared with conventional standard chemotherapy. Subsequently, echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK), a novel driver oncogene, has been found in 2007. Crizotinib, the first clinically available ALK tyrosine kinase inhibitor, appeared more effective compared with standard chemotherapy in NSCLC patients harboring EML4-ALK. The identification of EGFR mutations and ALK rearrangement in NSCLC has further accelerated the shift to personalized treatment based on the appropriate patient selection according to detailed molecular genetic characterization. This review summarizes these genetic biomarker-based approaches to NSCLC, which allow the instigation of individualized therapy to provide the desired clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=84878977499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878977499&partnerID=8YFLogxK

U2 - 10.2147/CMAR.S32973

DO - 10.2147/CMAR.S32973

M3 - Review article

C2 - 23785245

AN - SCOPUS:84878977499

VL - 5

SP - 91

EP - 101

JO - Cancer Management and Research

JF - Cancer Management and Research

SN - 1179-1322

IS - 1

ER -